SHENZHEN MOCHIKA TECHNOLOGY CO., LTD – Trademark Portfolio

Entity Type: 16

SHENZHEN MOCHIKA TECHNOLOGY CO., LTD holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include EFIOIST. The owner is based in LONGHUA DIST SHENZHEN.

NO. 89 XINLING RD, DALANG STREET,

608, UNIT 1, JINXING BUILDING,

LONGHUA DIST SHENZHEN 518000 , CN

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

EFIOIST
EFIOIST
Registered 2024
EFIOIST
EFIOIST
Registered 2020

Trademark Classifications

SHENZHEN MOCHIKA TECHNOLOGY CO., LTD's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

5
Pharmaceuticals (2 filings)

Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes

Frequently Asked Questions

How many trademarks does SHENZHEN MOCHIKA TECHNOLOGY CO., LTD have?

SHENZHEN MOCHIKA TECHNOLOGY CO., LTD has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does SHENZHEN MOCHIKA TECHNOLOGY CO., LTD file in?

SHENZHEN MOCHIKA TECHNOLOGY CO., LTD files trademarks across 1 Nice Classification class. The most active classes are Class 5 (Pharmaceuticals). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.

What are SHENZHEN MOCHIKA TECHNOLOGY CO., LTD's most well-known trademarks?

SHENZHEN MOCHIKA TECHNOLOGY CO., LTD's registered trademark portfolio includes well-known marks such as EFIOIST. These are among 2 currently registered trademarks in the portfolio.

What is SHENZHEN MOCHIKA TECHNOLOGY CO., LTD's trademark registration success rate?

SHENZHEN MOCHIKA TECHNOLOGY CO., LTD has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.